atuveciclib

Atuveciclib is a highly selective, orally bioavailable small molecule inhibitor of positive transcription elongation factor b (P-TEFb), which is composed of cyclin-dependent kinase 9 (CDK9) and cyclin-T. By binding to and inhibiting CDK9, atuveciclib prevents phosphorylation of the carboxyl terminal domain (CTD) of RNA polymerase II, thereby blocking transcriptional elongation by RNA Pol II. This inhibition leads to reduced expression of tumor-promoting genes, induction of apoptosis in tumor cells, and suppression of cell proliferation. Atuveciclib has demonstrated antineoplastic activity in preclinical models and early-phase clinical trials for advanced cancers and acute leukemia. It was initially developed by Bayer[1][2][3][4][6].

Other names

1414943-94-463Q7F59W0VUNII-63Q7F59W0VUNII63Q7F59W0VUNII 63Q7F59W0V